"Now is not the time to rehash an already settled debate on the effectiveness of MAT — but rather a time to point the megaphone in the right direction — towards our policy makers." @RyanForRecovery @DrSarahWakeman #WakeUpFDA https://t.co/l0p5yb8gmS
Opioid use disorder recovery is not one size fits all - we need more recovery options and a @US_FDA that will help, not hinder, treatment innovation. Learn more: https://t.co/4qqsgNWSaJ
#WakeUpFDA
The FDA should be doing everything in its power to help Americans safely access recovery options. Stand with us and say #WakeUpFDA! https://t.co/DqjdD647nF
The @US_FDA needs to own up to its mistakes in allowing the #opioidcrisis to get out of control. Here's what @FDACommissioner must do better: https://t.co/8OaYVhwzAb
Read our letter calling on @realDonaldTrump & @HHSGov@SecAzar to investigate the @US_FDA's failure to work in the best interest of Americans in #recovery by shirking oversight responsibilities and thwarting innovation and competition: https://t.co/iXD4h628JZ #WakeUpFDA
#Congress has the power to investigate the @US_FDA's decisions and demand action, transparency, and accountability on the #opioid crisis. Contact your representatives now! #WakeUpFDA https://t.co/PljzZ5fa4Z
The #FDA must put pain patient health & safety before #BigPharma by:
- Establishing post-market surveillance guidance
- Improving opioid risk evaluation and mitigation strategies & addressing the lack of uniform opioid prescriber education
#WakeUpFDA https://t.co/eboHi5GpXU
In an important step, the @US_FDA approved the first generic #naloxone nasal spray to treat opioid #overdose. Visit https://t.co/Lc7kson3sb to learn more about what the FDA must do to effectively support people living with addiction. https://t.co/gvb4p1SORK
There’s a complete lack of transparency into the inner workings of the @US_FDA and it’s about time someone held them accountable. Tell #Congress to take action: https://t.co/DqjdD647nF #WakeUpFDA